1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–62. [PubMed] 2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14. [PubMed] 3. Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am. 2004;33(1 Suppl 1):S1–9. [PubMed] 4. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–101. [PubMed]
5. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington: National Academies Press; 2010.
6. Klinkenberg WD, Caslyn RJ, Morse GA, Yonker RD, McCudden S, Ketema F, et al. Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders. Compr Psychiatry. 2003;44:293–302. [PubMed] 7. Schwarz KB, Garrett B, Alter MJ, Thompson D, Strathdee SA. Seroprevalence of HCV infection in homeless Baltimore families. J Health Care Poor Underserved. 2008;19:580–7. [PubMed] 8. Cheung RC, Hanson AK, Maganti K, Keeffe EB, Matsui SM. Viral hepatitis and other infectious diseases in a homeless population. J Clin Gastroenterol. 2002;34:476–80. [PubMed] 9. Desai RA, Rosenheck RA, Agnello V. Prevalence of hepatitis C virus infection in a sample of homeless Veterans. Soc Psychiatry Psychiatr Epidemiol. 2003;38:396–401. [PubMed] 10. Stein JA, Nyamathi A. Correlates of hepatitis C virus infection in homeless men: a latent variable approach. Drug Alcohol Depend. 2004;75:89–95. [PubMed] 11. Nyamathi AM, Dixon EL, Robbins W, Smith C, Wiley D, Leake B, et al. Risk factors for hepatitis C virus infection among homeless adults. J Gen Intern Med. 2002;17:134–43. [PMC free article] [PubMed] 12. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. High prevalence but low treatment rates. J Gen Intern Med. 2004;19:357–65. [PMC free article] [PubMed] 13. Strehlow AJ, Robertson MJ, Zerger S, Rongey C, Arangua L, Farrell E, et al. Hepatitis C among clients of health care for the homeless primary care clinics. J Health Care Poor Underserved. 2012 In press. [PubMed] 14. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol. 2005;3:311–8. [PubMed]
15. McKinney-Vento Homeless Assistance Act. Public Law 100-77 (1987)
16. Manly JJ, Bell-McGinty S, Tang MX, Schupf N, Stern Y, Mayeux R. Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol. 2005;62:1739–46. [PubMed] 17. Koegel P, Burnam MA, Farr RK. The prevalence of specific psychiatric disorders among homeless individuals in the inner city of Los Angeles. Arch Gen Psychiatry. 1988;45:1085–92. [PubMed] 18. Robertson MJ, Clark RA, Charlebois ED, Tulskey J, Long HL, Bangsberg DR, et al. HIV seroprevalence among homeless and marginally housed adults in San Francisco. Am J Public Health. 2004;94:1207–17. [PubMed] 19. Robertson MJ, Zlotnick C, Westerfelt A. Drug use disorders and treatment contact among homeless adults in Alameda County, California. Am J Public Health. 1997;87:221–8. [PubMed]
20. Smith EM, North CS, Spitznagel EL. Are hard-to-interview street dwellers needed in assessing psychiatric disorders in homeless men? Int J Methods Psychiatr Res. 1991;1:69–78.
21. Burnam MA, Koegel P. Methodology for obtaining a representative sample of homeless persons. The Los Angeles Skid Row Study. Eval Rev. 1988;12:117–52.
22. Vernez G, Burnam MA, McGlynn EA, Trude S, Mattman BS. Review of California's program for the homeless mentally disabled [R-3631-CDMH] Santa Monica (CA): The RAND Corp; 1988.
23. RAND Survey Research Group. Downtown health project hepatitis study summary report. Santa Monica (CA): RAND Corp; 2004.
24. Robins L, Cottler L, Bucholz K, Compton W. C-DIS-IV: computerized diagnostic interview schedule, version IV. St. Louis: Washington University in St. Louis Department of Psychiatry; 2000.
25. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998;88:108–13. [PubMed] 26. Des Jarlais DC, Hagen H, Arasteh K, McKnight C, Semaan S, Perlman DC. Can intranasal drug use reduce HCV infection among injecting drug users? Drug Alcohol Depend. 2011;119:201–6. [PubMed] 27. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm Rep. 2003;52(RR-3):1–13. 15. [PubMed]
28. SAS Institute, Inc. SAS®: Version 6.12. Cary (NC): SAS Institute, Inc; 1999.
29. Stata Corp. Stata®: Release 5. College Station (TX): Stata Corp; 1993.
30. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62. [PubMed]
31. Krawczynski K, Alter MJ, Robertson BH, Lu L, Spelbring JE, McCaustland KA. Environmental stability of hepatitis C virus (HCV): viability of dried/stored HCV in chimpanzee infectivity studies. Program and Abstracts of the 54th Annual Meeting of the American Society for the Study of Liver Disease; Philadelphia. W.B. Saunders; 2003.
33. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436–441. [PubMed] 35. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet. 2005;5:558–67. [PubMed] 36. Rosenblum A, Nuttbrock L, McQuistion HL, Magura S, Joseph H. Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis. 2001;20:15–25. [PubMed]
37. Williams IT, Boaz K, Openo K, Avent K, Bedell M, Gill J, et al. Incidence and risk factors for hepatitis C in the USA, 1982–2004: the role of injection drug use. J Clin Virol. 2006;36:S44.
38. Centers for Disease Control and Prevention (US) Hepatitis surveillance report #61. Department of Health and Human Services, Public Health Service (US); 2006.
39. Cook PA, McVeigh J, Syed Q, Mutton K, Bellis MA. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction. 2001;96:1787–97. [PubMed] 40. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais DC, Flom PL, et al. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend. 2007;89:1–12. [PMC free article] [PubMed] 41. Ko YC, Ho Ms, Chiang TA, Chang SJ, Chang PY. Tattooing as a risk of hepatitis C virus infection. J Med Virol. 1992;38:288–91. [PubMed] 42. Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore) 2001;80:134–51. [PubMed] 43. Haley RW, Fischer RP. The tattooing paradox. Arch Intern Med. 2003;163:1095–8. [PubMed] 44. Nishioka SA, Gyorkos TW, Joseph L, Collet JP, MacLean JD. Tattooing and risk for transfusion-transmitted diseases: the role of the type, number and design of the tattoos, and the conditions in which they were performed. Epidemiol Infect. 2002;128:63–71. [PubMed] 45. Nishioka SA, Gyorkos TW, Joseph L, Collet JP, MacLean J. Tattooing and transfusion-transmitted diseases in Brazil: a hospital-based cross-sectional matched study. Eur J Epidemiol. 2003;18:441–9. [PubMed] 47. Silverman AL, Sekhon JS, Saginaw SJ, Wiedbrauk D, Balasubramaniam M, Gordon SC. Tattoo application is not associated with an increased risk for chronic viral hepatitis. Am J Gastroenterol. 2000;95:1312–5. [PubMed] 48. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(3 Suppl 1):62S–65S. [PubMed]
49. Dienstag JL. Acute viral hepatitis. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine. 18th ed. Volumes 1 and 2. New York: McGraw-Hill; 2011. pp. 2537–57.
50. Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg DR. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS. 2005;19(Suppl 3):S208–14. [PubMed] 51. Neale J. Homelessness, drug use and hepatitis C: a complex problem explored within the context of social exclusion. Int J Drug Policy. 2008;19:429–35. [PubMed]
52. Dennis ML. Changing the conventional rules: surveying homeless people in nonconventional locations. Housing Policy Debates. 1991;2:701–32.
53. Burt MR, Aron LY, Douglas T, Valente J, Lee E, Iwen B. Homelessness: programs and the people they serve—summary report. Washington: Urban Institute; 1999.
54. Breakey WR, Fischer PJ, Kramer M, Nestadt G, Romanoski AJ, Ross A, et al. Health and mental health problems of homeless men and women in Baltimore. JAMA. 1989;262:1352–7. [PubMed]